When Roche Holding AG executives held an investor-day briefing in New York in March, Morgan Stanley analyst Andrew Baum had a question that had nothing to do with new drugs, licensing deals or health-care legislation.
The U.S. could save almost $3 billion a year if Medicare patients were given Avastin instead of Lucentis to treat two diseases that could lead to blindness, according to a study in the journal Health Affairs.
Napoleone Ferrara, professor at UC San Diego School of Medicine, joins Tiziana Life Sciences as chairman of scientific advisory board and consultant, co. says in statement. * Co. developing experimental treatment for late-stage breast cancer targeting BCL3 gene * “I look forward to advising the company’s scientists as they work towards human trials for this promising therapeutic gene technology”: Ferrara * NOTE: Tiziana started trading on AIM on April 24 * NOTE: Ferrara in 2010 won Lasker Award, which often foretells future Nobel Prize winners * NOTE: Avastin for colorectal, breast, lung, kidney, ovarian cancers and glioblastoma had CHF6.25b ($7b) in sales last yr
Apotex Inc. must face a Roche Holding AG lawsuit claiming its generic version of Valcyte, which treats a virus that afflicts transplant patients and people with AIDS, infringes a Roche patent that expires in 2015.